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be observed in the posterior pituitary lobe in consecutive 
semithin sections. We also found strong immunoreactiv-
ity for SHBG in epithelial cells of the choroid plexus and 
in a portion of the ependymal cells lining the third ven-
tricle. Mass spectrometry showed that affi nity-purifi ed 
SHBG from the hypothalamus and choroid plexus is struc-
turally similar to the SHBG identifi ed in the CSF. The mul-
tiple localizations of SHBG suggest neurohypophyseal 
and neuroendocrine functions. The biochemical data sug-
gest that CSF SHBG is of brain rather than blood origin. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 Sex hormone-binding globulin (SHBG) is a glycopro-
tein that has been identifi ed in several tissues of different 
mammalian species. Alternate splice variants and glyco-
sylation of SHBG have been observed in different tissues. 
The outcome of this is a specifi c molecular weight pattern 
of the expressed protein in the different tissues  [1–4] . Our 
laboratory and others have reported an intrinsic expres-
sion of SHBG in the hypothalamus of rats  [5, 6] . 
 One model of SHBG action suggests that it is a carrier 
protein for steroids  [7] while a more recent model suggests 
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 Abstract 
 Gonadal steroids are known to infl uence hypothalamic 
functions through both genomic and non-genomic path-
ways. Sex hormone-binding globulin (SHBG) may act by 
a non-genomic mechanism independent of classical ste-
roid receptors. Here we describe the immunocytochemi-
cal mapping of SHBG-containing neurons and nerve fi -
bers in the human hypothalamus and infundibulum. Mass 
spectrometry and Western blot analysis were also used 
to characterize the biochemical characteristics of SHBG in 
the hypothalamus and cerebrospinal fl uid (CSF) of hu-
mans. SHBG-immunoreactive neurons were observed in 
the supraoptic nucleus, the suprachiasmatic nucleus, the 
bed nucleus of the stria terminalis, paraventricular nucle-
us, arcuate nucleus, the perifornical region and the me-
dial preoptic area in human brains. There were SHBG-im-
munoreactive axons in the median eminence and the 
infundibulum. A partial colocalization with oxytocin could 
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that SHBG may bind to a membrane receptor to induce 
a rapid steroid effects through a G-protein-mediated pro-
cess  [ for review, see  8] . This receptor has been function-
ally identifi ed in a number of tissues including prostate, 
testis, breast, liver and brain  [8–12], its structural features 
however are still unknown. Recent fi ndings show that 
SHBG-like proteins secreted from sexually dimorphic 
structures in the rodent lacrimal and submandibular 
glands may serve as pheromones  [13] . 
 Little is known about the functional importance of 
SHBG in the brain. It has been shown that SHBG coupled 
to estradiol may play a role in the stimulation of oxytocin 
release in the rat hypothalamus  [14] . Intraventricular in-
fusions of SHBG, with and without bound estradiol, fa-
cilitate female sexual receptivity in rats while SHBG cou-
pled to dihydrotestosterone blocks this effect  [15, 16] , 
however the effects have not been tested in humans. 
 The aim of the present study was to assess the distri-
bution of SHBG in the human hypothalamus, choroid 
plexus and infundibulum. SELDI-TOF mass spectrom-
etry was used to characterize the SHBG molecule ex-
pressed in the hypothalamus and to compare its structure 
with that of serum SHBG, which is known to be expressed 
in liver, and with SHBG from the cerebrospinal fl uid. 
 Materials and Methods 
 Tissue 
 Human hypothalami, both male (n = 4) and female (n = 3) 
(mean age 69  8 14 years) with a mean postmortem time  ! 30 h, 
were obtained from the Department of Pathology, FSU-Jena. Ex-
periments were approved by the Ethics Commission, FSU Jena, 
protocol No. 1065-03/03. 
 After dissection of the retrochiasmatic portion of the hypothal-
ami, including the mammillary bodies, tissue samples were fi xed 
by immersion in 4% paraformaldehyde for at least 3 weeks, dehy-
drated and embedded in paraffi n. Small blocks containing the hy-
pophysial stalk and the median eminence (ME) were dissected and 
fi xed separately for 1 day in the same fi xative prior to dehydration 
in ascending ethanol series and embedding in Epon for semithin 
sectioning. Unfi xed samples of hypothalamus and choroid plexus 
(n = 3) were dissected and frozen at –80  °  C for biochemical analysis. 
Cerebrospinal fl uid (CSF) samples were obtained from a depart-
mental collection of control samples  [ for details, see  17] . Serum 
samples were collected from 4 volunteer medical students in the 
laboratory. Both CSF and serum samples were stored at –80  °  C un-
til biochemical investigation. 
 Immunocytochemistry 
 Eight- to 10-  m thick serial frontal sections were cut on a 
Reichert microtome and mounted on glycerol and egg albumin-
coated glass slides. After removal of the paraffi n with xylene and 
rehydration, sections were washed in phosphate-buffered saline 
(PBS) for 2 h followed by treatment with 3% H 2 O 2  and 10% meth-
anol in PBS for 20 min at room temperature (RT), to block endog-
enous peroxidase activity. After washing in PBS for 1 h, PBS con-
taining 2% normal goat serum was applied for 2 h. After another 
washing step in PBS, sections were incubated in anti-SHBG over-
night at 4  °  C. We used a mouse monoclonal antibody (clone 16D5, 
for production and characterization see Lewis et al.  [18] ) at a dilu-
tion of 1:  250 in PBS containing 2% BSA (PBS-BSA). Sections were 
then washed in PBS and incubated in biotin-conjugated goat anti-
mouse IgG (Vector Laboratories, 1:  150 in PBS-BSA, 2 h at RT). 
After washing, streptavidin-peroxidase-complex was applied (Vec-
tor Laboratories 1:  150 in PBS-BSA, 2 h at RT). The immunoreac-
tion was visualized with freshly prepared 3  ,3  -diaminobenzidine 
(DAB) and H 2 O 2  in PBS (reagents were obtained from Sigma). Af-
ter staining, sections were rinsed in distilled water and then dehy-
drated through an ascending series of ethanol and mounted in En-
tellan ®  (Merck). Immunocytochemical controls were performed 
with normal goat serum instead of SHBG antibody or with anti-
SHBG preabsorbed with synthetic SHBG (100 ng/1 ml antiserum 
in the fi nal dilution). 
 Serial 1-  m-thick semithin sections of the infundibulum and 
the ME were incubated in 10% sodium methoxide for 2 min, to 
remove epoxy resin, prior to immersion in PBS. Consecutive sec-
tions were stained either for SHBG, as described above, or for oxy-
tocin (OT). Rabbit antiserum to OT (Chemicon AB 911) was used 
at a dilution of 1:  1,000 in PBS overnight at 4  °  C. Immunoprecipi-
tates were visualized with anti-rabbit IgG 1:  100 for 1 h and rabbit 
PAP complex 1:  100 in PBS and stained with DAB (all reagents 
obtained from Sigma, Munich). Stained slides were coverslipped 
with Entellan ® . 
 Sections were examined with an Olympus BX50 microscope 
equipped with a digital camera, Olympus DP10 and DP-Soft 3.0 
software for microphotography. Anatomical locations of the la-
beled cells were determined according to the cytoarchitectonic de-
scriptions of Mai et al.  [19] . 
 For control purposes, SHBG antibody was preincubated with 
the antigen before being applied to the tissue sections. To prevent 
the cross-reaction of the second antibodies, we omitted the anti-
SHBG step in a further control experiment. 
 Purifi cation of SHBG 
 For mass spectrometric analysis, human hypothalamic tissues 
were homogenized mechanically followed by sonication in lysis buff-
er (0.1  M NaPH 4  pH 7.5 containing 2 m M MgCl 2  (Sigma), 0.5% 
(v/v), CHAPS (Sigma), 5 m M EDTA (Sigma), 0.02 m M PMSF (Sig-
ma), 0.1 m M leupeptin (Serva), 0.04   l/ml   -mercaptoethanol (Sig-
ma); 5 ml/hypothalamus) and centrifuged at 10,000  g at 3  °  C for 
30 min. CSF and the serum samples were centrifuged the same way. 
 SHBG was purifi ed from the supernatant of the probes using 
IDM affi nity beads (Chipergen Biosystems, Inc.). 10   l protein A 
(Sigma) were coupled onto 5   l of the beads. Monoclonal SHBG 
antibody from mouse (clone 16D5) was incubated on the protein 
A coupled beads overnight at 4  °  C. Binding capacity of protein A 
beads is 10 mg/ml IgG in 1 ! PBS. We incubated 500   l of each 
tissue sample with 10   l protein A-anti-SHBG beads overnight at 
4  °  C in an end-over-end mixer. After washing, bound SHBG was 
eluted with 50% (v/v) acetonitrile in 0.5% (v/v) trifl uoroacetic acid 
for mass spectrometric analysis. Alternatively, we used polyclonal 
anti-ABP (653 and 882) raised in rabbit diluted 1:  10 in PBS to elute 
SHBG from the column. For details of preparation, characteriza-
tion and specifi city of these antibodies, see Becchis et al.  [20] . 
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 SELDI-TOF MS Analysis 
 Surface-enhanced laser desorption ionization-time of fl ight 
mass spectrometry (SELDI-TOF) analysis was applied to deter-
mine the mass of the bound proteins on the beads. 3   l of the elut-
ed probes were dried on the hydrophobic surface of a H4 chip array 
after spots were washed with 27% (v/v) acetonitrile in 0.1  M PBS 
(pH 7.4). We used 2  ! 0.5   l saturated sinapic acid as matrix solu-
tion. The chip arrays were analyzed in a ProteinChip Reader (PBS-
II; Chipergen Biosystems, Inc.) according to an automated data 
collection protocol  [21] . The instrument was used in positive ion 
mode. Laser intensity was set at 300 (corresponding to approxi-
mately 200   J), using a nitrogen laser, emitting at 337 nm. The 
digitizer was operated at 250 MHz. 105 transients were averaged 
over 66% of the target area in a linear sweep to generate each spec-
trum. Bovine serum albumin and chicken conalbumin were used 
for external calibration. A deviation exceeding 0.3% from the pro-
tein standard was considered signifi cant. We used Chipergen Pro-
teinChip Software 3.1 to data analysis and representation. 
 PBS instead of tissue extract was applied to the protein A beads 
coupled to anti-SHBG as a control. We also coupled anti-corticoste-
roid-binding globulin to the protein A beads to test for the specifi c-
ity of binding of the beads complex. The eluted samples were exam-
ined in both cases with mass spectrometry as described above. 
 Fig. 1. Localization of SHBG-immunoreac-
tive structures in the human hypothalamus. 
 A–E Diagrams of frontal hypothalamic sec-
tions from anterior to posterior (arc = arcu-
ate nucleus; bnst = bed nucleus of the stria 
terminalis; bstc = central nucleus of the bed 
nucleus of the stria terminalis; bnst-pm = 
posteriomedial component of the bed nu-
cleus of the stria terminalis; CA = anterior 
commissure; fo = perifornical region; FX = 
fornix; inf = infundibulum; pvn = paraven-
tricular nucleus; scn = suprachiasmatic nu-
cleus; son = supraoptic nucleus; rson = ret-
rochiasmatic part of the supraoptic nucleus; 
ME = median eminence; NO = optic nerve; 
TO = optic tract; XO = optic chiasm; III = 
third ventricle). Asterisks represent SHBG-
IR cells. Circles represent immunoreactive 
fi bers. The number of asterisks and circles 
indicate the relative number of the stained 
structures in the distinct areas.  F Sagittal 
view of the hypothalamus for the exact lo-
calization of the frontal sections. CM = 
Mammillary bodies.
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 Western Blot Analysis 
 Further samples of eluted protein were reconstituted in 20   l 
SDS-gel loading buffer (Novagen, Inc.) and boiled for 5 min. Elec-
trophoresis was performed in 4–10% (10 v/w) polyacrylamide gra-
dient gel. Following SDS-PAGE, protein bands were blotted at 
400 Vh, 20  °  C onto PVDF membranes (Amersham) in blotting buff-
er (6.35 g Tris base, 3.62 g glycine, 50 ml methanol in 250 ml dis-
tilled water). SHBG was visualized with the ABC method as de-
scribed above. Rabbit protein-weight marker mix (Novagen) was 
used as molecular weight references. 
 Results 
 Localization of SHBG in the Human Hypothalamus 
 An overview of the hypothalamic SHBG distribution 
is given in  fi gure 1 . SHBG immunoreactivity could be 
detected in the perikarya of neurons and ependymal cells 
and in nerve fi bers. No labeling in the nucleus could be 
observed. SHBG-immunoreactive (SHBG-IR) cells and 
fi bers could be found in the magnocellular portions of bed 
nucleus of the stria terminalis (bnst) ( fi g. 1 A–D), supra-
optic nucleus (son) ( fi g. 1 A–F,  fi g. 2 A,B), paraventricular 
nucleus (pvn) ( fi g. 1 D,E,  fi g. 2 C, arrowhead) and the per-
ifornical region (fo) ( fi g. 1 E). Single stained cells were 
found distributed in the medial preoptic area (mpoa) ( fi g. 
1 C). SHBG-IR cells were also detected rostral to the pvn 
in the posterior part of the hypothalamus ( fi g. 1 E), an area 
that does not correspond to any previously described hy-
pothalamic nucleus. Scattered parvocellular neurons 
were labeled in the arcuate nucleus (arc) ( fi g. 1 E) and in 
the pvn ( fi g. 2 C, arrows). 
 Several immunoreactive fi bers were seen in the infun-
dibulum ( fi g. 1 D,E,  fi g. 3 A). Strong arborization of stained 
fi bers was seen in the ME ( fi g. 1 D,  fi g. 2 D) and in the su-
 Fig. 2. SHBG-labeled structures in the hu-
man hypothalamus.  A A group of labeled 
magnocellular neurons in the son.  B Higher 
magnifi cation suggests cytoplasmic staining 
of SHBG in the neurons of the SON. The 
neuronal nuclei showed no immunoreactiv-
ity.  C A population of labeled magnocellu-
lar (black arrowheads) and parvocellular 
(arrow) neurons in the paraventricular nu-
cleus. In the neuropil associated with the 
third ventricle (III) is a specifi c immuno-
staining for SHBG. Scattered cells in the 
ependyma are SHBG positive (empty ar-
rowheads).  D SHBG-immunoreactive fi ber 
network with varicosities (arrowheads) in 
the ME.  E SHBG-labeled epithelial cells in 
the choroid plexus.  F No immunoreactivity 
was detected in the case of omitted primary 
antibody. Photo was taken in the PVN close 
to the third ventricle. Scale bars: 10   m for 
 B ,  D ,  E ; 20   m for  A ,  F , and 40   m for  C . 
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prachiasmatic nucleus (SCN), while stained perikarya 
were only seen in the anterior part of this nucleus ( fi g. 
1 D). SHBG-IR cells were also found in a small portion of 
the ependymal cells, lining the third ventricle ( fi g. 2 C, 
empty arrowheads) and in most of the epithelial cells of 
the choroid plexus ( fi g. 2 E, arrowheads). Diffuse SHBG-
IR occurred in the neuropil surrounding the third ven-
tricle ( fi g. 2 C); this staining was particularly abundant in 
the mpoa. Immunostaining was completely absent in the 
immunocytochemical controls ( fi g. 2 F), indicating that 
neuronal staining was specifi c for SHBG-IR. 
 In semithin sections it was possible to identify distinct 
axonal varicosities in the ME and the infundibulum. Ex-
amination of consecutive semithin sections revealed co-
existence of SHBG ( fi g. 3 A) with OT ( fi g. 3 B) in identical 
axons. 
 Mass Analysis of the SHBG Protein 
 SELDI-TOF MS analysis identifi ed two protein peaks 
with different molecular weights which were specifi cally 
bound to the monoclonal SHBG antibody ( fi g. 4 ). A 
49,605  8 6 Da protein peak was identifi ed in the human 
hypothalamus (HT), CSF, serum and choroid plexus. A 
53,909-Da protein was found only in the serum. The con-
trol experiments showed only a 48,367-Da protein signal, 
which is under-represented in the tissue probes. This peak 
represents an immunoglobulin heavy chain molecule 
originating from the eluted antibody. The second control 
experiment proving the specifi city of the protocol showed 
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 Fig. 3. Consecutive semithin section of in-
fundibulum immunostained for SHBG 
shows specifi c reaction product in single ax-
onal varicosities ( A ). The subsequent sec-
tion reveals coexistence with OT in some of 
these structures ( B ). Different arrowheads 
show examples of axons immunoreactive 
for both OT and SHBG. Scale bar: 5   m. 
 Fig. 4. SELDI-TOF analysis of the affi nity beads purifi ed human 
tissue probes. PC: Plexus choroideus; HT: hypothalamus; CSF: ce-
rebrospinal fl uid; SER: serum. A 49,605  8 6 Da protein could be 
identifi ed in all the studied tissue probes. The 53,909-Da protein 
was found only in the blood plasma. C1: The fi rst control experi-
ment showed a 48,367-Da protein, which resembles eluted anti-
body. C2: Second control experiment shows spectrum of a hypo-
thalamus sample eluted from unspecifi c antibody coupled beads. 
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 Western Blot Analysis 
 Western blot analysis of the purifi ed samples showed 
bands at two different molecular weights ( fi g. 5 ). A 
49-kDa protein band could be found in all tissue probes, 
while a higher mass protein (around 53 kDa) was only 
seen in the serum sample. During this process the anti-
body was not detected in the mass interval presented. 
 Discussion 
 Our immunocytochemical fi ndings describe for the fi rst 
time cellular localization and distribution of SHBG in the 
human hypothalamus. We found that neuronal perikarya 
and fi bers were detected in the magnocellular supraoptic 
nucleus, bed nucleus of the stria terminalis, paraventricu-
lar nucleus, perifornical nucleus, arcuate nucleus and in 
the parvocellular suprachiasmatic nucleus. SHBG-IR fi -
bers were detected throughout the hypothalamic nuclei, in 
the ME and in the infundibulum. The staining of fi bers in 
hypothalamus, ME and infundibulum indicates that 
SHBG is most likely subject to axonal transport to the pos-
terior pituitary lobe. It seems possible that posterior pitu-
itary SHBG is liberated into the systemic circulation along 
with OT. This is also supported by previous immunoelec-
tron microscopical studies, which show SHBG localized in 
posterior pituitary secretory vesicles in the rat where it is 
colocalized with OT  [22] . Further, evidence that SHBG in 
the hypothalamus shows the same characteristics as SHBG 
from secretory organs such as the testis and mouse lacrimal 
glands  [13, 23] may indicate that it is packaged in synaptic 
vesicles for extracellular release. 
 The presence of immunoreactive SHBG in human hy-
pothalamus suggests its involvement in human neuro-
physiology and possibly neuropathology. Our behavioral 
data in rats suggest that SHBG is important in control of 
reproductive behaviors  [15, 16] . The observation that es-
tradiol levels control brain SHBG expression  [24] also 
suggests that SHBG is involved in neuroendocrine con-
trol. Serum SHBG levels have been shown to increase in 
patients with Alzheimer’s disease  [25, 26] . Further stud-
ies need to be done to demonstrate whether changes in 
central SHBG exist in various neurodegenerative ail-
ments. 
 The distribution of the labeled structures overlaps 
with the known location of hypothalamic neuropeptide 
OT. In semithin sections we found coexistence of OT and 
SHBG in neurohypophysial projections, indicating that 
both are packaged for transport out of the cell bodies, pos-
sibly into the posterior pituitary. We have previously 
demonstrated the colocalization of SHBG and OT in the 
rat hypothalamic nuclei and posterior pituitary  [6, 27] . 
 Our SELDI-TOF MS and Western blot studies show 
two SHBG molecules with different molecular weights. 
We confi rmed evidence that there is a 53-kDa SHBG pro-
tein in blood serum, which is known to originate from 
hepatocytes  [28] . This 53-kDa moiety did not appear in 
the brain. However, a 49-kDa protein was identical in the 
hypothalamus and CSF that was also seen in blood serum. 
Alternatively, spliced and glycosylated variants of SHBG 
have been demonstrated in various species and in differ-
ent tissues. The 49-kDa molecular weight could be identi-
fi ed as the SHBG variant, ABP (testosterone-estrogen-
binding protein; nomenclature from Swiss-Prot Protein 
knowledgebase. Englebienne and Doyen  [29]  showed a 
distinct SHBG in the serum, with a molecular weight sim-
ilar to the one we found. They interpreted this as originat-
ing from the testis. 
 We suggest that SHBG in the CSF is rather of brain 
origin than from blood. A portion of the hypothalamic 
neuroendocrine cells in humans is likely to express SHBG. 
Wang et al.  [5] demonstrated SHBG production in rat 
brain using Northern blots while we used RT-PCR to 
identify production of SHBG in the rat brain  [24] . There-
fore, it is likely that the SHBG immunoreactivity identi-
fi ed in this study in humans is also produced in the 
brain. 
 SHBG, liberated from liquor contacting neurons  [30] 
in the PVN, may enter the CSF, which would account for 
the observed diffuse immunostaining of the periventricu-
lar neuropil. Staining of ependymal and plexus epithelial 
cells could be due to expression or uptake of the steroid-
binding globulin by those cells. It is known that ependy-
mal cells are connected by gap junctions to the periven-
tricular neurons, thus allowing proteins from CSF to enter 
the surrounding neuropil. 
 Fig. 5. Western blot analysis of the affi nity beads purifi ed human 
tissue probes. Blot shows proteins eluted with polyclonal SHBG 
antibody from the beads. Two distinct SHBG-immunoreactive 
proteins with different molecular weights are present in the exam-
ined tissues: a smaller one in the hypothalamus, choroid plexus, 
serum and in the CSF. In serum an additional larger protein was 
observed. HT: hypothalamus; p: plexus choroideus; scf: spinal cord 
fl uid; s: serum; C: control; SHBG antibody. 
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 The CSF is known to contain signifi cant levels of 
SHBG  [31] , which shows alteration at different physio-
logical and pathological stages such as in Alzheimer’s dis-
ease  [26] . 
 The extensive distribution of both SHBG-IR neurons 
and processes suggests multiple functional properties. 
SHBG may be synthesized and released into blood along 
with the neurohypophysial hormones. Intrahypothalamic 
SHBG may be released within the brain where it com-
bines with neurosteroids to control the modulation of 
mood and behavior. 
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